Zongertinib in Previously Treated <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Zongertinib showed clinical benefit with mainly low-grade adverse events in patients with previously treated <i>HER2</i>-mutant NSCLC. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.).
Authors
- Kiyotaka Yoh
- Ernest Nadal (ORCID: https://orcid.org/0000-0002-9674-5554)
- Maren Rohrbacher
- Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
- Joshua K. Sabari (ORCID: https://orcid.org/0000-0002-1556-1543)
- David Planchard (ORCID: https://orcid.org/0000-0002-1565-8310)
- Noboru Yamamoto (ORCID: https://orcid.org/0000-0002-0787-2851)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5740-9654)
- John Victor Heymach (ORCID: https://orcid.org/0000-0001-9068-8942)
- Yanqiu Zhao (ORCID: https://orcid.org/0000-0003-0161-6184)
- Hai‐Yan Tu (ORCID: https://orcid.org/0000-0001-7125-9878)
- Yi-Long Wu (ORCID: https://orcid.org/0000-0002-3611-0258)
- Jon Zugazagoitia (ORCID: https://orcid.org/0000-0001-9352-5882)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Ute von Wangenheim
- Behbood Sadrolhefazi
- Nicolas M Girard (ORCID: https://orcid.org/0000-0001-9909-2299)
- Sabina Eigenbrod-Giese
- G. Ruiter
Institutions
- Boehringer Ingelheim (Germany) (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Yonsei University (KR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Leiden University Medical Center (NL)
- Institut Gustave Roussy (FR)
- Samsung Medical Center (KR)
- The Netherlands Cancer Institute (NL)
- Zhengzhou University (CN)
- Research Institute Hospital 12 de Octubre (ES)
- NYU Langone Health (US)
- National Cancer Center (US)
- Institut Català d'Oncologia (ES)
- Oncode Institute (NL)
- Henan Cancer Hospital (CN)
- Institut du Thorax (FR)
- National Cancer Center Hospital East (JP)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Boehringer Ingelheim (United States) (US)
- Southern Medical University (CN)
- Institut Curie (FR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-28
- DOI
- https://doi.org/10.1056/nejmoa2503704
- Citations
- 56
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 85.03
Funders
- Boehringer Ingelheim